In situ gene therapy for prostate cancer: immunomodulatory approaches (Q34452001)

2 August 2017

1 reference

title

In situ gene therapy for prostate cancer: immunomodulatory approaches (English)

1 reference

2 August 2017

0 references

1 reference

Thompson TC

1

1 reference

2 August 2017

Timme TL

2

1 reference

2 August 2017

Ebara S

3

1 reference

2 August 2017

Satoh T

4

1 reference

2 August 2017

Yang G

5

1 reference

2 August 2017

Wang J

6

1 reference

2 August 2017

Miles BJ

7

1 reference

2 August 2017

Ayala G

8

1 reference

2 August 2017

Wheeler TM

9

1 reference

2 August 2017

Kadmon D

10

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 May 2001

1 reference

Expert Opinion on Biological Therapy

2 August 2017

published in

1 reference

2 August 2017

volume

1

1 reference

2 August 2017

issue

3

1 reference

2 August 2017

page(s)

481-495

1 reference

2 August 2017

cites work

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

Progress in transcriptionally targeted and regulatable vectors for genetic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

Strategies to adapt adenoviral vectors for targeted delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

The promoter of the prostate-specific antigen gene contains a functional androgen responsive element

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

Prostate-specific antigen expression is regulated by an upstream enhancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

Evaluation of the biodistribution, persistence, toxicity, and potential of germ-line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

A recombinant adenovirus expressing p27Kip1 induces cell cycle arrest and loss of cyclin-Cdk activity in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

Antisense c-myc retroviral vector suppresses established human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

Improved artificial death switches based on caspases and FADD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

Metabolic suicide genes in gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

In vivo gene therapy of cancer with E. coli purine nucleoside phosphorylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

Inhibition by acyclovir of cell growth and DNA synthesis of cells biochemically transformed with Herpesvirus genetic information

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

Regression of established macroscopic liver metastases after in situ transduction of a suicide gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

Cancer gene therapy: a bystander effect using the gap junctional pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

Mechanism of 'bystander effect' killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

The role of cytokines in mediating the bystander effect using HSV-TK xenogeneic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

Characterization of the antitumor immune response generated by treatment of murine tumors with recombinant adenoviruses expressing HSVtk, IL-2, IL-6 or B7-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

A family of bicistronic vectors to enhance both local and systemic antitumor effects of HSVtk or cytokine expression in a murine melanoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

Ganciclovir chemoablation of herpes thymidine kinase suicide gene-modified tumors produces tumor necrosis and induces systemic immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

The "bystander effect": association of U-87 cell death with ganciclovir-mediated apoptosis of nearby cells and lack of effect in athymic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

The use of adenoviral vectors for gene therapy and gene transfer in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

Genetic predisposition and mesenchymal-epithelial interactions in ras+myc-induced carcinogenesis in reconstituted mouse prostate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

Progression to androgen insensitivity in a novel in vitro mouse model for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

Mouse prostate reconstitution model system: A series of in vivo and in vitro models for benign and malignant prostatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

Cooperative therapeutic effects of androgen ablation and adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

Cytopathic effect of in situ gene therapy in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

IL-12: initiation cytokine for cell-mediated immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

Interleukin-12: a recently discovered cytokine with potential for enhancing cell-mediated immune responses to tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

Antitumor and antimetastatic activity of interleukin 12 against murine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

Interleukin 12: a new clinical player in cytokine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

Induction of effective antitumor immunity in a mouse brain tumor model using B7-1 (CD80) and intercellular adhesive molecule 1 (ICAM-1; CD54) transfection and recombinant interleukin 12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

Direct Intratumoral Injection of an Adenovirus Expressing Interleukin-12 Induces Regression and Long-Lasting Immunity That Is Associated with Highly Localized Expression of Interleukin-12

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.1.3.481

21 January 2018

Identifiers

DOI

10.1517/14712598.1.3.481

1 reference

2 August 2017

1 reference